Your shopping cart is currently empty

Nebentan (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan . Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively[1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo[2].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $197 | Inquiry | Inquiry | |
| 10 mg | $332 | Inquiry | Inquiry | |
| 25 mg | $581 | Inquiry | Inquiry | |
| 1 mL x 10 mM (in DMSO) | $224 | Inquiry | Inquiry |
| Description | Nebentan (YM598) is a potent, selective and orally active non-peptide endothelin ETA receptor antagonist through the modification of Bosentan . Nebentan inhibits [125I] endothelin-1 binding to cloned human endothelin ETA and ETB receptor, with Ki of 0.697 nM and 569 nM, respectively[1]. YM598 can ameliorate the progression of cor pulmonale and myocardial infarction in vivo[2]. |
| Targets&IC50 | ETA:0.697 nM (Ki), ETB:569 nM (Ki) |
| In vitro | Nebentan inhibits the specific binding of [125I] endothelin-1 to endothelin ETA and ETB receptors in a concentration-dependent manner, with Ki values of 0.697 nM and 1.53 nM for human and rat endothelin ETA receptors, respectively. In contrast, YM598 exhibits low affinities for human and rat endothelin ETB receptors, with Ki values of 569 nM and 155 nM, respectively [1]. Nebentan also inhibits the endothelin-1-induced increase in intracellular Ca2+ concentration ([Ca2+]i) in both CHO and A10 cells, with IC50 values of 26.2 nM and 26.7 nM, respectively [1]. |
| In vivo | Nebentan, administered orally at dosages of 0.1-1 mg/kg for 4 weeks, significantly impedes the advancement of pulmonary hypertension and the formation of right ventricular hypertrophy. Additionally, when administered at a dosage of 1 mg/kg over 30 weeks, it markedly improves the survival rates of CHF rats, significantly reducing the hypertrophy of both ventricles and alleviating pulmonary congestion. |
| Molecular Weight | 491.52 |
| Formula | C24H21N5O5S |
| Cas No. | 403604-85-3 |
| Smiles | COc1ccccc1Oc1c(NS(=O)(=O)\C=C\c2ccccc2)nc(nc1OC)-c1ncccn1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (254.31 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 3.3 mg/mL (6.71 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.